BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35014537)

  • 21. Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218.
    Timon G; Ciardo D; Bazani A; Marvaso G; Riva G; Volpe S; Rojas DP; Renne G; Petralia G; Zerini D; Fodor C; Dicuonzo S; Maestri D; Pansini F; Cambria R; Cattani F; Golino F; Scroffi V; De Lorenzo D; De Cobelli O; Orecchia R; Jereczek-Fossa BA
    Br J Radiol; 2018 Sep; 91(1089):20160725. PubMed ID: 29750539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.
    Hoeks CM; Schouten MG; Bomers JG; Hoogendoorn SP; Hulsbergen-van de Kaa CA; Hambrock T; Vergunst H; Sedelaar JP; Fütterer JJ; Barentsz JO
    Eur Urol; 2012 Nov; 62(5):902-9. PubMed ID: 22325447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiparametric-Magnetic Resonance/Ultrasound Fusion Targeted Prostate Biopsy Improves Agreement Between Biopsy and Radical Prostatectomy Gleason Score.
    Porpiglia F; DE Luca S; Passera R; Manfredi M; Mele F; Bollito E; DE Pascale A; Cossu M; Aimar R; Veltri A
    Anticancer Res; 2016 Sep; 36(9):4833-9. PubMed ID: 27630337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
    Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
    Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
    Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
    Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The added value of systematic biopsy in men with suspicion of prostate cancer undergoing multiparametric MRI-targeted biopsy.
    Mannaerts CK; Kajtazovic A; Lodeizen OAP; Gayet M; Engelbrecht MRW; Jager GJ; Wijkstra H; de Reijke TM; Beerlage HP
    Urol Oncol; 2019 May; 37(5):298.e1-298.e9. PubMed ID: 30660493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Prospective Comparison of Selective Multiparametric Magnetic Resonance Imaging Fusion-Targeted and Systematic Transrectal Ultrasound-Guided Biopsies for Detecting Prostate Cancer in Men Undergoing Repeated Biopsies.
    Boesen L; Nørgaard N; Løgager V; Balslev I; Thomsen HS
    Urol Int; 2017; 99(4):384-391. PubMed ID: 28651247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accuracy of MRI-Targeted in-Bore Prostate Biopsy According to the Gleason Score with Postprostatectomy Histopathologic Control--a Targeted Biopsy-Only Strategy with Limited Number of Cores.
    Garmer M; Busch M; Mateiescu S; Fahlbusch DE; Wagener B; Grönemeyer DH
    Acad Radiol; 2015 Nov; 22(11):1409-18. PubMed ID: 26343218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
    van der Leest M; Cornel E; Israël B; Hendriks R; Padhani AR; Hoogenboom M; Zamecnik P; Bakker D; Setiasti AY; Veltman J; van den Hout H; van der Lelij H; van Oort I; Klaver S; Debruyne F; Sedelaar M; Hannink G; Rovers M; Hulsbergen-van de Kaa C; Barentsz JO
    Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective nonrandomized study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy to magnetic resonance imaging with subsequent MRI-guided biopsy in biopsy-naïve patients.
    Castellucci R; Linares Quevedo AI; Sánchez Gómez FJ; Díez Rodríguez J; Cogorno L; Cogollos Acuña I; Salmerón Béliz I; Muñoz Fernández de Legaría M; Martínez Piñeiro L
    Minerva Urol Nefrol; 2017 Dec; 69(6):589-595. PubMed ID: 29094851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Focusing on MRI-suspected lesions in targeted transrectal prostate biopsy guided by MRI-TRUS fusion imaging for the diagnosis of prostate cancer].
    Qu HW; Liu H; Cui ZL; Jin XB; Zhao Y; Wang MW; Song W; Zhang XJ
    Zhonghua Nan Ke Xue; 2016 Sep; 22(9):782-786. PubMed ID: 29071873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Prostate Imaging Reporting and Data System Classification in the Prediction of Tumor Aggressiveness in Targeted Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy.
    Borkowetz A; Platzek I; Toma M; Renner T; Herout R; Baunacke M; Laniado M; Baretton GB; Froehner M; Zastrow S; Wirth MP
    Urol Int; 2017; 99(2):177-185. PubMed ID: 28531902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MRI-directed biopsy for primary detection of prostate cancer in a population of 223 men: MRI In-Bore vs MRI-transrectal ultrasound fusion-targeted techniques.
    Del Monte M; Cipollari S; Del Giudice F; Pecoraro M; Bicchetti M; Messina E; Dehghanpour A; Ciardi A; Sciarra A; Catalano C; Panebianco V
    Br J Radiol; 2022 Mar; 95(1131):20210528. PubMed ID: 34609900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis.
    Choi YH; Kang MY; Sung HH; Jeon HG; Chang Jeong B; Seo SI; Jeon SS; Kim CK; Park BK; Lee HM
    Clin Genitourin Cancer; 2019 Feb; 17(1):e19-e25. PubMed ID: 30415878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study.
    Panebianco V; Barchetti F; Sciarra A; Ciardi A; Indino EL; Papalia R; Gallucci M; Tombolini V; Gentile V; Catalano C
    Urol Oncol; 2015 Jan; 33(1):17.e1-17.e7. PubMed ID: 25443268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer.
    Kamrava M; Kishan AU; Margolis DJ; Huang J; Dorey F; Lieu P; Kupelian PA; Marks LS
    Pract Radiat Oncol; 2015; 5(6):411-6. PubMed ID: 26059510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
    Ullrich T; Arsov C; Quentin M; Laqua N; Klingebiel M; Martin O; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
    Eur J Radiol; 2019 Apr; 113():1-6. PubMed ID: 30927932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. "In-bore" MRI-guided Prostate Biopsy Using an Endorectal Nonmagnetic Device: A Prospective Study of 70 Consecutive Patients.
    Schiavina R; Vagnoni V; D'Agostino D; Borghesi M; Salvaggio A; Giampaoli M; Pultrone CV; Saraceni G; Gaudiano C; Vigo M; Bianchi L; Dababneh H; La Manna G; Chessa F; Romagnoli D; Martorana G; Brunocilla E; Porreca A
    Clin Genitourin Cancer; 2017 Jun; 15(3):417-427. PubMed ID: 28258961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Real-time MRI/US fusion-guided biopsy in biopsy-naïve and pre-biopsied patients with suspicion for prostate cancer].
    Maxeiner A; Stephan C; Fischer T; Durmus T; Kilic E; Asbach P; Haas M; Günzel K; Neymeyer J; Miller K; Cash H
    Aktuelle Urol; 2015 Jan; 46(1):34-8. PubMed ID: 25519051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MRI-based radiomics signature for localized prostate cancer: a new clinical tool for cancer aggressiveness prediction? Sub-study of prospective phase II trial on ultra-hypofractionated radiotherapy (AIRC IG-13218).
    Gugliandolo SG; Pepa M; Isaksson LJ; Marvaso G; Raimondi S; Botta F; Gandini S; Ciardo D; Volpe S; Riva G; Rojas DP; Zerini D; Pricolo P; Alessi S; Petralia G; Summers PE; Mistretta FA; Luzzago S; Cattani F; De Cobelli O; Cassano E; Cremonesi M; Bellomi M; Orecchia R; Jereczek-Fossa BA
    Eur Radiol; 2021 Feb; 31(2):716-728. PubMed ID: 32852590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.